We improve the lives of patients through the design of precise cancer therapeutics. Until now, RSK has been undruggable. Our work focuses on developing novel drugs targeting RSK, a driver in cancerous tumor growth and metastases.
In the News: Why RSK? A leading oncologist explains.
In a recent OncLive feature, Dr. Hung Khong of Banner MD Anderson Cancer Center walks through the science behind PMD-026 and its potential to help patients with RSK-driven breast cancer — a group that has historically faced limited treatment options.
https://www.onclive.com/view/rsk-inhibition-is-poised-for-deeper-activity-in-rsk-high-cdk4-6-inhibitor-resistant-breast-cancer